Evaluation of new anti-infective drugs for the treatment of infectious arthritis in adults

C. Norden, J. D. Nelson, J. T. Mader, G. B. Calandra

Research output: Contribution to journalArticle

Abstract

This guideline describes clinical trials of new anti-infective drugs for the treatment of septic arthritis due to bacteria other than Neisseria gonorrhoeae in adults. Septic arthritis is associated with fever and with physical findings at the affected joint. Diagnosis is established by culture of synovial fluid. Treatment includes the administration of antimicrobial drugs and drainage of the joint by needle aspiration or surgery. Multicenter, randomized comparative clinical trials that are single-, double-, or evaluator-blinded should be performed. However, an open trial of a new antimicrobial agent with historical controls is acceptable. Patients should receive treatment for at least 2-3 weeks. After 5 days of antimicrobial therapy, synovial fluid should be sterile and clinical signs and symptoms should have diminished. Patients should be followed for 2-4 weeks after completion of therapy.

Original languageEnglish (US)
JournalClinical Infectious Diseases
Volume15
Issue numberSUPPL. 1
StatePublished - 1992

Fingerprint

Infectious Arthritis
Pharmaceutical Preparations
Synovial Fluid
Joints
Therapeutics
Neisseria gonorrhoeae
Anti-Infective Agents
Signs and Symptoms
Needles
Drainage
Fever
Randomized Controlled Trials
Clinical Trials
Guidelines
Bacteria

ASJC Scopus subject areas

  • Immunology

Cite this

Evaluation of new anti-infective drugs for the treatment of infectious arthritis in adults. / Norden, C.; Nelson, J. D.; Mader, J. T.; Calandra, G. B.

In: Clinical Infectious Diseases, Vol. 15, No. SUPPL. 1, 1992.

Research output: Contribution to journalArticle

@article{68b07cec65064367a4350664a1eb720b,
title = "Evaluation of new anti-infective drugs for the treatment of infectious arthritis in adults",
abstract = "This guideline describes clinical trials of new anti-infective drugs for the treatment of septic arthritis due to bacteria other than Neisseria gonorrhoeae in adults. Septic arthritis is associated with fever and with physical findings at the affected joint. Diagnosis is established by culture of synovial fluid. Treatment includes the administration of antimicrobial drugs and drainage of the joint by needle aspiration or surgery. Multicenter, randomized comparative clinical trials that are single-, double-, or evaluator-blinded should be performed. However, an open trial of a new antimicrobial agent with historical controls is acceptable. Patients should receive treatment for at least 2-3 weeks. After 5 days of antimicrobial therapy, synovial fluid should be sterile and clinical signs and symptoms should have diminished. Patients should be followed for 2-4 weeks after completion of therapy.",
author = "C. Norden and Nelson, {J. D.} and Mader, {J. T.} and Calandra, {G. B.}",
year = "1992",
language = "English (US)",
volume = "15",
journal = "Clinical Infectious Diseases",
issn = "1058-4838",
publisher = "Oxford University Press",
number = "SUPPL. 1",

}

TY - JOUR

T1 - Evaluation of new anti-infective drugs for the treatment of infectious arthritis in adults

AU - Norden, C.

AU - Nelson, J. D.

AU - Mader, J. T.

AU - Calandra, G. B.

PY - 1992

Y1 - 1992

N2 - This guideline describes clinical trials of new anti-infective drugs for the treatment of septic arthritis due to bacteria other than Neisseria gonorrhoeae in adults. Septic arthritis is associated with fever and with physical findings at the affected joint. Diagnosis is established by culture of synovial fluid. Treatment includes the administration of antimicrobial drugs and drainage of the joint by needle aspiration or surgery. Multicenter, randomized comparative clinical trials that are single-, double-, or evaluator-blinded should be performed. However, an open trial of a new antimicrobial agent with historical controls is acceptable. Patients should receive treatment for at least 2-3 weeks. After 5 days of antimicrobial therapy, synovial fluid should be sterile and clinical signs and symptoms should have diminished. Patients should be followed for 2-4 weeks after completion of therapy.

AB - This guideline describes clinical trials of new anti-infective drugs for the treatment of septic arthritis due to bacteria other than Neisseria gonorrhoeae in adults. Septic arthritis is associated with fever and with physical findings at the affected joint. Diagnosis is established by culture of synovial fluid. Treatment includes the administration of antimicrobial drugs and drainage of the joint by needle aspiration or surgery. Multicenter, randomized comparative clinical trials that are single-, double-, or evaluator-blinded should be performed. However, an open trial of a new antimicrobial agent with historical controls is acceptable. Patients should receive treatment for at least 2-3 weeks. After 5 days of antimicrobial therapy, synovial fluid should be sterile and clinical signs and symptoms should have diminished. Patients should be followed for 2-4 weeks after completion of therapy.

UR - http://www.scopus.com/inward/record.url?scp=0026443581&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026443581&partnerID=8YFLogxK

M3 - Article

VL - 15

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

SN - 1058-4838

IS - SUPPL. 1

ER -